<DOC>
	<DOCNO>NCT00167687</DOCNO>
	<brief_summary>This double-blind placebo control pilot trial test hypothesis prazosin , alpha-1 adrenergic receptor antagonist , reduce alcohol consumption alcohol crave alcohol dependent individual without Post Traumatic Stress Disorder ( PTSD ) . The intervention period six week .</brief_summary>
	<brief_title>Prazosin Alcohol Dependence IVR Study</brief_title>
	<detailed_description>The objective project determine whether prazosin , alpha-1 adrenergic receptor antagonist , decrease alcohol consumption and/or subjective experience alcohol crave individual without post-traumatic stress disorder ( PTSD ) seek treatment alcohol dependence . The study hypothesis : ( 1 ) Subjects treat prazosin report few drinking day few drink per drinking day subject treat placebo , ( 2 ) subject treat prazosin report decrease crave alcohol compare subject placebo condition , ( 3 ) prazosin well-tolerated propose dosage subject prazosin condition compare subject placebo condition . This project double-blind , randomize , placebo-controlled trial prazosin subject dependent alcohol use alcohol within last 30 day prior randomization . The treatment phase last 6 week include 40 subject ; 20 randomize experimental condition ( prazosin placebo ) . Participants group provide behavioral treatment alcohol dependence throughout course study . Participants group also use daily Interactive Voice Response ( IVR ) symptom monitor technology track daily fluctuation alcohol use craving , well medication compliance . The study conduct Addiction Treatment Center ( ATC ) VAPSHCS , Seattle division . Participants include 40 alcohol-dependent adult present chemical dependency treatment VA Puget Sound Health Care System ( VAPSHCS ) Addiction Treatment Center well subject recruit general public via advertisement local weekly newspaper . Study Procedures : Once potential study participant undergone initial screen insure basic eligibility provide inform consent undergo 2-hour baseline assessment include complete diagnostic interview , paper-and-pencil packet measure , provide urine blood specimen . After completion assessment , final determination make within three business day whether potential participant meet inclusion exclusion criterion . Eligible participant randomize one two treatment group . The participant prompt three time day text message page remind take study medication . The behavioral treatment use study Medication Management protocol adapt procedure use Project COMBINE . A clinical rescue strategy place participant evidence severe clinical deterioration include consume 140 standard equivalent drink 7 day period remove protocol offer inpatient treatment VA PSHCS . During first two week study , participant twice-weekly orthostatic vital sign adverse event monitor study nurse physician , weekly thereafter . All serious unexpected adverse event report FDA UW Human Subjects Committee accordance requirement . When participant complete medication treatment 6 week post-randomization , repeat baseline measure laboratory test ( urine blood sample request ) except PCL California Verbal Learning Test .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>age 18 year age old current DSMIV diagnosis alcohol dependence use last 30 day capacity provide inform consent plan absence six week active treatment period would prevent weekly checkin wiht study psychiatrist English fluency Score 50 great PTSD Check List suggest current diagnosis PTSD Psychiatric disorder require medication antidepressant Current diagnosis opiate dependence abuse , chronic treatment opiatecontaining medication previous month , urine positive opioids Significant acute chronic medical illness , include unstable angina , recent myocardial infarction , history congestive heart failure , preexist hypotension ( systolic low 110 ) orthostatic hypotension ( systolic drop great 20mmHg two minute stand drop dizziness ) , insulindependent diabetes mellitus ; chronic renal hepatic failure , pancreatitis , gout , Meniere 's disease , benign positional vertigo , narcolepsy Concomitant use trazodone , tadalafil verdenafil History prazosinsensitivity Women pregnant , nurse infant ( ) , childbearing potential use contraceptive method judge investigator effective Signs symptom alcohol withdrawal time randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>